A Phase 1-2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Trial Profile

A Phase 1-2, Open-Label Study of The X-Linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2012

At a glance

  • Drugs AEG 35156 (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Aegera Therapeutics
  • Most Recent Events

    • 12 Jul 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 19 Jul 2010 Interim results in 13 patients treated in phase I part of study reported in an Aegera Therapeutics media release.
    • 27 Jan 2010 Phase I is complete and the phase II portion of trial has been initiated, according to Aegera Therapeutics Inc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top